hrp0094p2-391 | Pituitary, neuroendocrinology and puberty | ESPE2021

Cushing’s disease in paediatric patients: Diagnosis and evolution

Messaoudi Najoua , Assarrar Imane , Bouichrat Nisrine , Karrou Marouan , Rouf Siham , Latrech Hanane ,

Introduction: Cushing’s syndrome is rare in the paediatric population, affecting 0.89 per million children between the ages of 0 and 20 years. The causes of Cushing’s syndrome of endogenous origin are dominated by pituitary causes in 70-95%, with a peripubertal revelation. We report the case of a child followed for Cushing’s disease in the department of Endocrinology-Diabetology-Nutrition of Mohammed-VI University Hospital Center of Oujda, in th...

hrp0097p1-222 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Height evaluation in a group of patients with Prader Willi syndrome after 3 years of treatment with growth hormone

Lara Emma , Castel Molineli Ana , Pintado Mónica , Luis Ruibal Jose

Introduction: Prader–Willi syndrome (PWS) is a genetic disorder caused by the lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 region. Clinical picture of PWS changes across life stages. PWS is characterized by endocrine abnormalities, such as growth hormone (GH) deficiency, obesity, central adrenal insufficiency, hypothyroidism, hypogonadism, and complex behavioural and intellectual difficulties. The recombinant human growt...

hrp0097p1-500 | GH and IGFs | ESPE2023

Factors influencing response to growth hormone therapy in patients with growth hormone deficiency

Nguyen Thi Hang , Bui Phuong Thao , Nguyen Ngoc Khanh , Can Thi Bich Ngoc , Do Thi Thanh Mai , Nguyen Thu Ha , Nguyen Trong Thanh , Vu Chi Dung

Keywords: recombinant human growth hormone (rhGH), growth hormone deficiency (GHD), short statureBackground: Recombinant growth hormone is used for the treatment of growth hormone deficiency. In children treated early, catch-up growth is excellent, with a normal final height. A final height gain of 30 cm can be expected on average. However, it has long been recognized that there is variability in the magnitude of individ...

hrp0097p2-63 | Diabetes and Insulin | ESPE2023

The importance of genetic testing and the appropriate use of glibenclamide in neonatal diabetes

Tumasyan Dalar , Bayburdyan Gayane , Hovakimyan Marina , Arakelyan Lusine , Aghajanova Elena

Introduction: Neonatal diabetes is a rare condition that can present in the first months of life. Neonatal diabetes has more than 20 genetic origins that are currently known. About 40% of these patients carry mutations in KCNJ11 and ABCC8 genes, which impair the pancreatic beta-cell K-ATP channels and can be treated with oral sulfonylureas. The purpose of this case report is to present a patient diagnosed with neonatal diabetes and the subsequent management of...

hrp0095fc1.1 | Thyroid | ESPE2022

Neonatal TSH screening for congenital hypothyroidism: before discharge or at home?

Boros Emese , Marcelis Lionel , Van Vliet Guy , Elilie Mawa Ongoth Farel , Heinrichs Claudine , Brachet Cecile

In Belgium, neonatal TSH screening for congenital hypothyroidism has been performed between day 3 and 5 of life since the late seventies. In January 2015, a policy of early discharge of healthy neonates was implemented so that the neonatal screening strategy had to be adapted. Between January 2015 and September 2019, dried blood spot sampling was mostly collected at home AFTER discharge at 72 h of life (Newborn Screening Strategy 1 (NBS1)). After October 2019, sampling was mos...

hrp0095p1-1 | Adrenals and HPA Axis | ESPE2022

Collection of salivary steroids in children under conditions replicating home sampling

Tonge Joseph , Keevil Brian , Craig Jessica , Langley Joe , Whitaker Martin , Ross Richard , Elder Charlotte

Background: Measurement of salivary glucocorticoids is an accepted method for testing adrenal function and is gaining popularity as it offers a non-invasive collection technique, enabling sampling in the community or home environment, allowing tailored capture of steroid circadian rhythm and improved patient experience. However, there is little data on stability during home collection and sampling methods in young children. Current salivary collection techniqu...

hrp0095p1-24 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

SIADH as presenting feature of foramen magnum stenosis in a 2-month-old infant with achondroplasia (ACH): case report and discussion on management of infants with ACH in order to reduce the risk of serious complications

Nurcan Cebeci Ayse , Hebert Steven , Reutter Heiko , Wölfle Joachim

Background and Aim: Achondroplasia is the most common skeletal dysplasia and is associated with serious complications such as foramen magnum stenosis (FMS). Current guidelines in Germany recommend polysomnography at 2-3 months and cranial imaging at 6-9 months of life in achondroplasia, whereas American Academy of Pediatrics recommends to evaluate every infant with achondroplasia for cranio-cervical junction risks via neurologic examination, polysomnography an...

hrp0095p1-483 | Fat, Metabolism and Obesity | ESPE2022

The ecology of the microbiome in children with congenital generalized lipodystrophy type 4 (CGL4) is quickly modified after metreleptin treatment

Mancioppi Valentina , Daffara Tommaso , Caputo Marina , Bellone Simonetta , Massa Nadia , Caramaschi Alice , Mignone Flavio , Romanisio Martina , Rabbone Ivana , Giordano Mara , Aimaretti Gianluca , Bona Elisa , Prodam Flavia

Introduction: Lipodystrophy syndromes are characterized by a progressive metabolic impairment secondary to adipose tissue dysfunction and genetic background. The role of microbiota is still uninvestigated.Objective: Evaluate the gut microbiome ecology in relation to dietary and clinical parameters in two infant siblings with congenital generalized lipodystrophy type 4 (CGL4) before and after treatment with recombinant le...

hrp0095p1-534 | Multisystem Endocrine Disorders | ESPE2022

Successful treatment of neonatal Cushing in a paediatric patient with McCune Albright Syndrome (MAS) by using metyrapone suppositories

Ertl Diana-Alexandra , Ratzinger-Stoeger Gerda , Anzengruber Maria , Skoll Katharina , Raimann Adalbert , Gabor Franz , Haeusler Gabriele

We present the case of a now 20 months old female patient, in whom we diagnosed MAS on the basis of pseudoprecocious puberty and hypercorticism at the age of 10 months. Medical history and photodocumentation suggested that symptoms of hypercorticism were present soon after birth. At age 4 months thelarche had occurred, followed by vaginal bleeding at age 5 months. At first presentation at our outpatient clinic, the girl was severely short (-5 SDS), with only minimally advanced...

hrp0095p2-256 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Case report: Roumanian baby with cytochrome P450 oxidoreductase deficiency

Simona Fica , Luminita Cima , Ana Zubaci , Raluca Oprescu

Background: POR deficiency is a rare form of congenital adrenal hyperplasia, transmitted in an autosomal recessive trait, that is characterized by ambiguous genitalia, impaired steroidogenesis and skeletal malformations similar to those of Antley-Bixler syndrome. It is caused by mutations in the P450 oxidoreductase gene (POR), an electron donor for all microsomal P450 enzymes including the three steroidogenic enzymes P450c 17 (17 alfa-hidroxylase /17,20 lyase)...